Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI
Phase 4
78
about 1.8 years
18+
1 site in FL
What this study is about
This trial is testing whether de-escalating dual antiplatelet therapy (DAPT) by reducing the dose of prasugrel or switching from a more potent P2Y12 inhibitor to clopidogrel provides similar benefits for preventing blood clots after heart procedures. The goal is to compare these two methods of DAPT de-escalation and determine if they are equally effective at preventing bleeding while still protecting against clots.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Prasugrel 5 mg
- 2.Take clopidogrel 75 mg
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
prasugrel, clopidogrel (Antiplatelet; blocks ADP receptors on platelets to prevent aggregation)
oral (Oral Tablet), oral
Cardiology / Heart